骨化三醇,β干扰素治疗协同作用减少诱发炎症反应刺激PBMCs (P1.192)

文摘

目的:β干扰素和越来越多的活性代谢物的维生素D是公认的免疫调节活动。我们试图评估治疗的影响外周血单核细胞(PBMCs)与骨化三醇及/或干扰素β细胞因子刺激后的生产。方法:一群22名健康成人的血液样本是由标准的静脉穿刺。PBMCs 100 iu骨化三醇治疗和/或100或400 iuβ干扰素,或者什么都没有,然后与Concanavilin a上层清液刺激评估- 2、il - 4、il - 6、il - 10, IL-17,移行细胞和tnf。通过线性回归预测的细胞因子评估。研究结果:22个受试者招募。相对于单独的刺激,骨化三醇显著降低生产- 2、il - 4、il - 6, IL-17和移行。β干扰素治疗显著降低il - 6和tnf,同时增加il - 10和IL-17剂量依赖性的方式。添加β干扰素骨化三醇增加il - 4、il - 10和IL-17,而il - 6和tnf是降低了。添加骨化三醇β干扰素减少2、il - 4、il - 6, IL-17,移行,il - 4和il - 6在一种添加剂的方式增加β干扰素的剂量。 No consistent interactions by sex or 25(OH)D status were found. Discussion: This is the first study to evaluate the effects of combined calcitriol and interferon-beta therapy on cytokine production in stimulated PBMCs. In addition to immunomodulatory effects of calcitriol and interferon-beta alone, we found their combination yielded greater reductions in Th1 and Th17 cytokines and greater increases in Th2 cytokines. These results indicate a potential utility in the combination of vitamin D-based therapies with interferon-beta in the treatment of MS and other conditions.

披露:Stewart博士没有披露。van der梅博士没有披露。泰勒博士没有披露。辛普森博士没有披露。